MariMed Inc. Reports 6.1% Revenue Growth to $41.9 Million in Q2 2026

MariMed Inc. reported a revenue increase of 6.1% for the second quarter of 2026, reaching $41.9 million compared to $39.5 million in the same period of 2025. For the first half of 2026, total revenue was $81.4 million, up 5.2% from $77.4 million in the prior year. The growth in revenue was primarily driven by a 4.0% increase in retail sales, which amounted to $23.2 million, and an 8.1% rise in wholesale sales, totaling $18.5 million. Despite the revenue growth, the company reported a net loss of $3.6 million for the quarter, compared to a loss of $1.4 million in the same quarter of the previous year.

In terms of operational performance, MariMed's cost of revenue increased by 9.0% to $25.7 million for the second quarter, leading to a gross profit of $16.2 million and a gross margin of 38.7%, down from 40.3% in the prior year. The increase in costs was attributed to higher production-related expenses and employee costs, which were partially offset by reductions in inventory-related expenses. Operating expenses also rose by 6.0% to $15.8 million, driven by increases in general and administrative costs and marketing expenses.

Strategically, MariMed completed the acquisition of First State Compassion Center (FSC) in March 2025, which has since contributed to the company's financial results. The company also restructured its Series B Convertible Preferred Stock in February 2026, extinguishing the previous obligation and issuing new promissory notes totaling $8 million. This restructuring resulted in a non-cash gain of $0.7 million recognized in the first quarter of 2026. The company continues to focus on expanding its product offerings and distribution networks, particularly in Delaware and Maryland.

As of June 30, 2026, MariMed's total assets were reported at $197.2 million, a decrease from $202.6 million at the end of 2025. The company had cash and cash equivalents of $8.4 million, down from $8.9 million at the end of the previous year. The total liabilities increased to $147.1 million, primarily due to higher mortgages and notes payable. The company’s employee headcount remained stable, with personnel expenses slightly increasing due to higher wages and commissions.

Looking ahead, MariMed anticipates continued growth in revenue driven by its strategic initiatives, including the launch of new products and expansion into new markets. The company is also monitoring changes in regulatory environments that may impact its operations. However, it acknowledges potential risks related to market conditions and the ongoing challenges of operating within the cannabis industry, which remains illegal at the federal level in the United States.